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Abstract  30 
Osteoarthritis (OA) is characterized by the loss of articular cartilage. In this study, we 
performed a peptidomic strategy to identify endogenous peptides (neopeptides) that are 
released from human osteoarthritic tissue, which may serve as disease markers. With this 
aim, conditioned media of osteoarthritic and healthy articular cartilages obtained from 
knee and hip were analyzed by shotgun peptidomics. This discovery step led to the 35 
identification of 1175 different peptides, corresponding to 101 proteins, as products of 
the physiological or pathological turnover of cartil ge extracellular matrix. Then, a 
targeted multiple reaction monitoring-mass spectrometry method was developed to 
quantify the panel of best marker candidates on a larger set of samples (n=62). Statistical 
analyses were performed to evaluate the significance of the observed differences and the 40 
ability of the neopeptides to classify the tissue. Eight of them were differentially abundant 
in the media from wounded zones of OA cartilage compared to the healthy tissue 
(p<0.05). Three neopeptides belonging to Clusterin and one from Cartilage Oligomeric 
Matrix Protein showed a disease-dependent decrease specifically in hip OA, whereas two 
from prolargin (PRELP) and one from Cartilage Interm diate Layer Protein 1 were 45 
significantly increased in knee OA. The release of one peptide from PRELP showed the 
best metrics for tissue classification (AUC=0.834). The present study reveals specific 
neopeptides that are differentially released from knee or hip OA cartilage compared to 
healthy tissue. This evidences the intervention of characteristic pathogenic pathways in 
OA and provides a novel panel of candidates for biomarker development.  50 
The proteomic data have been deposited to the ProteomeXchange Consortium via the 
PRIDE partner repository with the data set identifier PXD011800. 
 





Osteoarthritis (OA) is the most common arthritic disease [1]. It is already one of the 10 
most disabling pathologies in developed countries, b coming even more prevalent as the 
population ages and obesity rates rise. This disease is clinically silent in most patients i  
their early stages; thus the deterioration of cartilage (one of the hallmarks of OA) is 60 
already extensive at the time of diagnosis. Therefore, the development of strategies for 
early diagnosis and accurate monitoring of disease progression is among the major 
research goals in OA. 
OA is characterized by the loss of structural constituents from the extracellular matrix 
(ECM) of articular cartilage [2]. The ECM maintains and supports chondrocytes within 65 
their natural physicochemical micro-environment [3], and the degradation and release of 
cartilage proteins can vary according to the stage of the disease process. Therefore, the 
presence of cartilage-characteristic proteins and their degradation products in both 
proximal or peripheral body fluids, such as synovial fluid, blood or urine has been 
extensively evaluated to asses their biomarker usefuln ss. As examples confirming this 70 
hypothesis, the increase of the type II collagen fragment CTXII in urine has demonstrated 
a predictive value for disease progression [4, 5], and elevated levels of cartilage 
oligomeric matrix protein (COMP) in serum are correlat d with the presence of OA and 
disease severity [6]. Altogether, the ability to detect biomarkers of cartilage degradation 
and/or inflammation in biological samples, such as c rtilage, serum, urine or synovial 75 
fluid, may be helpful to improve OA diagnosis, predict its progression and/or develop 
effective therapeutic strategies. In this area, proteomics has emerged as a powerful tool 
for biomarker discovery in OA research [7, 8]. The term “peptidomics” was introduced 
as a branch derived from proteomics to define the quantitative and qualitative analysis of 
endogenous peptides (also named neopeptides) in biological samples, primarily by liquid 80 
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chromatography (LC) or biochip platforms coupled to various forms of mass 
spectrometry (MS) [9]. A specific neopeptide can be rel ased from a protein due to the 
existence or progression of a specific disease. Therefore, peptidomics has been appealing 
for biomarker studies because the knowledge that is generated may present a dynamic 
view of health status: peptides are created by a complex and fluid interaction of proteases, 85 
activators, inhibitors and protein substrates [10]. Due to many difficulties, biomarker 
discovery of endogenous peptides in complex samples is challenging and require 
systematic peptide extraction to achieve successful analysis [11].  
In this work, we aimed to characterize the profile of neopeptides present in conditioned 
media (secretomes) from human articular cartilage, and quantitatively compare these 90 
profiles between healthy and osteoarthritic tissues. This would allow not only to identify 
potential neopeptide biomarker candidates, but also to f ster the understanding of specific 
protease pathways that may be relevant for cartilage ECM destruction, which is the 
hallmark pathogenic process in OA.  
 95 
2. Materials and methods 
2.1 Cartilage samples 
Articular cartilage for the proteomic analysis was obtained either from femoral heads or 
condyles of patients with OA undergoing hip or knee r placement, and donors with no 
history of joint disease (N). All tissue samples were provided by the Tissue Bank and the 100 
Autopsy Service at Hospital Universitario de A Coruña. The study was approved by the 
local Ethics Committee (Galicia, Spain). OA patients were diagnosed following the 
criteria determined by the American College of Rheumatology [12].  Cartilage samples 
from 4 patients were used for the shotgun analysis (2 OA and 2 N), 21 were employed 
for MRM development (13 OA and 8 N), and 40 in the validation studies (22 OA and 18 105 




Table 1. Characteristics of the articular cartilage explants employed in this work. Two different 
explants were obtained per OA tissue (one from the UZ and another from the WZ). Thus, the 
number of samples analyzed is duplicated for OA cartilage. 110 
Screening 
 Dx n % Female Age (mean±SD) Mankin (mean) 
 N 2 33.3 77.33±4.16 1.5 
 OA 2 0 66±11.31 2.5 (UZ) 7.6 (WZ) 
Total number of samples   6 
MRM Development 
 Dx n % Female Age (mean±SD) Mankin (mean)  
Hip N 6 33.3 77.67±8.16 1.5 
 OA 5 100 82.2±6.02 3.6 (UZ) 6.2 (WZ) 
Knee N 2 0 56±2.83 1.5 
 OA 8 62.5 82.5±9.26 3.2 (UZ) 9 (WZ) 
Total number of samples  34 
Validation 
 Dx n % Female Age (mean±SD) Mankin (mean)  
Hip N 13 38.46 76.38±12.24 1.7 
 OA 10 70 77.8±9.02 3.3 (UZ) 9.3 (WZ) 
Knee N 5 40 70.6±13.6 2.6 
 OA 12 41.67 73.93±6.97 5 (UZ) 9.8 (WZ) 
Total number of samples  62 
UZ: Unwounded zone of OA cartilage; WZ: Wounded zone f OA cartilage. 
 
2.2 Histological-histochemical grading of cartilage 
A modified Mankin score [13] was employed for the histopathological classification of 
the severity of lesions on all the cartilage samples employed in this work. Briefly, tissue 115 
sections (4 µm) were stained with hematoxylin and eosin to evaluate cellular architecture, 
and toluidine blue and safranin O/fast green to visual ze the matrix proteoglycan content. 
Three different aspects of the score were determined a d summed up: cartilage structure 
(0-7 points), cellular abnormalities (0-2 points) and matrix staining (0-4 points), leading 
to a scale that ranges between 0 and 13. The Mankin score 0–2 represents normal 120 
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cartilage, 3–5 superficial fibrillation, 6–7 moderate cartilage destruction, 8–10 severe 
damage of cartilage, and over 10 complete loss of cartilage. 
2.3 Explants Culture 
Tissue explants were obtained from the dissection of N and OA hip and knee cartilages 
as described previously [14]. Among the OA samples, we differentiated the wounded 125 
zones (WZ) from those corresponding to the area adjcent to the lesion, or unwounded 
zones (UZ). Three 6-mm explants were cut from each zone/condition using a sterile 
biopsy punch. After extensive washes with PBS, the discs were placed into 96-well plates 
(one disc/well), containing 200 µL of serum-free DMEM supplemented with 100 
units/mL penicillin and 100 µg/mL streptomycin to avoid contamination. Plates were 130 
incubated overnight at 37 °C, 5% CO2. The collection time line of conditioned media 
(secretomes) was optimized based on our previous experi nce [14] and after appraising 
representative peptidomic profiles along 7 days. Secretomes from day 1 were discarded 
and replaced with fresh medium. Then, they were colle ted at days 2 and 5 from each 
explant culture. Protein concentrations were determined by the Bradford assay, and the 135 
samples were frozen at -80O C until processing. 
2.4 Secretome Processing 
Secretomes from the same donor and condition (WZ, UZ or N) collected at days 2 and 5 
were mixed together in a total volume of 1200µL. The endogenous peptides were 
concentrated by ultrafiltration using Amicon Ultra-4 devices (10 kDa MWCO, Merck 140 
Millipore, Bedford, MA). The resulting eluted volumes (fractions comprising peptides of 
< 10 kDa), were dried in a vacuum concentrator. Thesamples were cleaned twice prior 
to LC-MS/MS analysis, first by homemade Stage Tips containing six C18 Solid Phase 
Extraction Disks (Empore), and then using NuTip C18 (Glygen). 
2.5 Preparation of samples for MRM quantification 145 
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Heavy stable synthetic isotope-labeled peptides (SIS peptides, crude purity) were 
purchased from Thermo Scientific, (USA). These peptid s incorporated a fully atom 
labeled 13C and 15N isotopes at the different amino acids (labeled position; mass shift) as 
Alanine (13C3,15N-Ala; +4 Da) (A), Proline (13C5,15N-Pro; +6 Da) (P), Valine (13C5,15N-
Val; +6 Da) (V), Leucine (13C6,15N-Leu; +7 Da) (L), Lysine (13C6,15N2-Lys; +8 Da) (K), 150 
or Arginine (13C6,15N4-Arg; +10 Da) (R). Individual stocks of each peptide ranging from 
2.25-19.5 µg/µL were made. Then, equal volumes of each peptide were mixed to make 
the standard mixture solution. Finally, a dilution f 1/5000 of this mixture was made as 
the stock solution in a concentration range of 1.78-1 .6 pmol/µL of each peptide. Aliquots 
were kept at -20C. The processed cartilage secretome samples used to develop the 155 
targeted MRM method were reconstituted in 7 µL of buf er A (0.1% Formic acid in 5% 
acetonitrile), whereas the set of samples used for the validation was reconstituted in 7 µL 
of the peptide stock solution. 
2.5 Discovery phase analysis by shotgun LC/MS-MS  
Six secretome desalted samples (n=6, 2 N, 2 UZ, 2 WZ) were dried, r suspended in 10 160 
µL of 0.1% formic acid (FA) and analyzed by LC-MS/MS in an Easy-nLC II system 
coupled to LTQ-Orbitrap-Velos-Pro mass spectrometer (Thermo Scientific). The 
peptides were concentrated by reverse phase chromatography using a 0.1mm × 20 mm 
C18 RP precolumn (Proxeon), and then separated using a 0.075mm x 100 mm C18 RP 
column (Proxeon) operating at 0.3 µL/min. Peptides were eluted using a 90-min gradient 165 
from 5 to 40% solvent B (Solvent A: 0,1% FA in water, solvent B: 0,1% FA, 80% 
acetonitrile in water). ESI ionization was performed using a Nano-bore emitters Stainless 
Steel ID 30 µm (Proxeon) interface. The Orbitrap resolution was set at 30.000. Peptides 
were detected in survey scans from 400 to 1600 amu (1 µscan), followed by ten data 
dependent MS/MS scans (Top 10), using an isolation width of 2 m/z units (in mass-to-170 
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charge ratio units), normalized collision energy of 35%, and dynamic exclusion applied 
during 30 seconds periods. The mass spectrometry proteomics data obtained from this 
analysis have been deposited to the ProteomeXchange Consortium via the PRIDE partner 
repository with the data set identifier PXD011800. 
2.7 Design and development of the Multiple Reaction Monitoring (MRM) method 175 
The target peptides were chosen based on three criteria: 1) peptides with the highest 
Χscore (>3) using the Proteome Discoverer 1.3 software, 2) peptides present in at least 4 
of the 6 secretomes analyzed in the discovery phase and 3) peptides belonging to cartilage 
ECM proteins. 54 peptide precursors and fragment ion masses were selected on this basis 
and assayed for MRM analysis. The five most intense transitions for each suitable 180 
precursor were selected based on data deposited in he MS/MS library using the Skyline 
software [15]. Endogenous and SIS pe tides were analyzed by LC-MS/MS using a 
nanoLC system (TEMPO, Eksigent) coupled to a 5500-QTRAP instrument (Sciex). After 
desalting with a C18 precolumn (5µm, 300A, 100µm*2cm, Acclaim PepMap, Thermo 
Scientific, USA) and a flow of 3 µL/min during 10 minutes, peptides were separated on 185 
C18 nanocolumns (75 µm id, 15 cm, 3µm, Acclaim PepMap 100, Thermo Scientific, 
USA) at a flow rate of 300 nL/min. The total 70 min gradient for the MRM method starts 
with 5% buffer B (0.1% Formic acid in 95% acetonitrile) for 3 min, 35% B from 3 until 
45 min, 95% B for 1 minute, hold for 10 minutes, and fi ally, equilibration of the column 
with 5% B during 15 min. The mass spectrometer was interfaced with nanospray sources 190 
equipped with uncoated fused silica emitter tips (20 µm inner diameter, 10 µm tip, 
NewObjective, Woburn, MA) and was operated in the positive ion mode. Skyline was 
used to predict and optimize collision energies (CE) and declustering potential (DP) for 
each peptide [15]. Q1 and Q3 were set to unit/unit resolution (0.7 Da) and the pause 
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between mass ranges was set to 3 ms. MRM analysis was conducted with up to 152 195 
transitions per run (dwell time, 15 ms; cycle time 3s). 
For the validation analyses, 23 peptides were selected and included in the final method 
based on the following criteria: good signal in theMRM method, co-elution of at least 3 
transitions and detection using the MIDAS workflow. With this aim, the best MRM 
transitions for these peptides were pooled in one sch duled-MRM method with a 45-min 200 
gradient, using retention times extracted during the assay refinement. Different detection 
windows were used and the signal was compared with the MRM-IDA acquisition 
methods. The detection window of 300 gave the best s nsitivity with a time window of 
±2.5 minutes due to the possible small differences in RT between different days. The 
signal was defined as the detection of all the transitions from the endogenous peptide 205 
exactly co-eluting with all the transitions from the stable isotope–labeled peptide. Table 
2 shows the final list of peptides quantified in this work, whereas Supplementary Table 1 
enumerates all transitions and settings for their analysis. All data obtained in this targeted 
proteomics MRM-based analysis have been uploaded to PeptideAtlas and can be accessed 




Table 2. Endogenous peptides quantified by LC-MRM in articular cartilage secretomes. Bold 
letters indicate the stable isotope-labeled amino acid in each peptide. 
Sequence Protein Name UNIPROT Acc No. 
NANTFISPQQR  
Matrix Gla protein sp|P08493|MGP 
NTFISPQQR  
AEPGIQLKAV 
Cartilage oligomeric matrix protein sp|P49747|COMP AVAEPGIQLK 
VLNQGREIVQT 
DEGDTFPLR  







SSGSGPFTDVRA   
Fibronectin sp|P02751|FINC 





Clusterin sp|P10909|CLUS ASHTSDSDVPSGVTEV   
GEDQYYLRVTTV  
SEDGTKASAATTAIL 
Glia-derived nexin sp|P07093|GDN 
AVAQTDLKEPLKV  





2.8 Data analysis 215 
Peptide identification from raw data from the LTQ-Orbitrap was carried out using the 
SEQUEST algorithm (Proteome Discoverer 1.3, Thermo Scientific). The following 
constraints were used for the searches: no enzyme and tolerances of 10 ppm for precursor 
ions and 0.8 Da for MS/MS fragment ions. Search against decoy database (integrated 
decoy approach) using false discovery rate (FDR) < 0.01. Data from the 5500 QTRAP 220 
were analyzed with ProteinPilot 4.0 (Sciex), using the Paragon algorithm as default search 
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program using no enzyme and modifications criteria. R w files were imported to Skyline 
and integration was manually inspected to ensure core t peak detection and accurate 
integration. After the unambiguously detection of selected peptides in the secretome 
samples, synthetic standard peptides were used for confirmatory analyses and 225 
quantitation. The Protease Specificity Prediction Server (PROSPER) tool [16] was 
employed to search enzymes putatively involved in the cleavage of the endogenous 
peptides that had been identified in this work.  
2.9 Statistical analysis 
A p < 0.05 was considered statistically significant d all statistical tests were two-sided. 230 
GraphPad Prism 5.0 (Graphpad, San Diego, CA, USA) was used to compare medians 
among the three different conditions of patients and controls (WZ-UZ-Control), and a 
Kruskal–Wallis test’s multiple comparison was used. Mann–Whitney U tests were 
performed to evaluate the significance of discrimination between the disease classes and 
the control cohort. Receiver operator characteristic (ROC) analysis was performed to 235 
quantify the overall ability of a peptide to classify the tissue as OA or healthy. The ROC 
curves were smoothed, compared and threshold computed using the R package pROC 
2018 [17]. 
 
3. Results 240 
3.1 Isolation and identification of endogenous peptides released from articular 
cartilage 
The experimental workflow followed for the peptidomic profiling of articular cartilage 
degradation in OA is summarized in Figure 1. The studies were performed on conditioned 
media from human articular cartilage explants, whose characteristics were assessed by 245 
Mankin scoring (Table 1). In the OA tissue, explants were obtained both from the 
macroscopically normal zone (unwounded zone, or UZ, with an average Mankin score of 
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3.52±0.92) and the lesion (wounded zone, or WZ, Mankin score of 8.38±1.47), to 
evaluate possible differences. Finally, the healthy cartilages analyzed in this work had a 
Mankin score of 1.76±0.48. 250 
 
Figure 1. Schematic workflow of the study. (1.5-column figure) 
 
To isolate the endogenous peptides present in the conditioned media, we explored 
different combinations of ultrafiltration and solid phase extraction (SPE), which led to 255 
the final protocol described in the Methods section 2.2. Days 2 and 5 of culture were 
selected as the best points for the peptidomic analysis, showing the highest number of 
unique peptides and the lowest serum contamination in the conditioned media. The 
screening step led to the identification of 1175 different peptides corresponding to 101 
unique proteins that were released from hip or knee articular cartilage to the conditioned 260 
media. The complete list of neopeptides that were ident fied, and their correspondent 
parent proteins, is shown in Supplementary Table 2. A higher number of peptides in OA 
compared to normal tissue was found, although the result was not statistically significant 
(p=0,17). The parent proteins identified with the highest score and highest number of 
peptides were ECM structural constituents, such as COMP, PRELP or FINC. Several of 265 
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them were specifically characteristic of the articular cartilage ECM, such as COMP, 
CILP1 or PRG4. 
3.2 Development of targeted methods for the quantitative analysis of endogenous 
peptides released from articular cartilage 
The peptides that show the highest identification score (>3) in the screening phase, where 270 
identified in the majority of samples and belong to pr teins expressed in articular cartilage 
were selected to develop a targeted analysis method based on MRM-mass spectrometry. 
The criteria for the selection of peptides in this phase is fully described in section 2.7. 54 
endogenous peptides (belonging to 17 proteins) wereexplored for the development of the 
method, which was carried out using secretome samples from eleven hip and 10 knee 275 
cartilages (Table 1). Then, the final MRM method was designed with the aid of SIS 
peptides for the detection and quantification of the 23 endogenous peptides showing the 
best performance (section 2.7), whose 9 parent proteins are expressed in human articular 
cartilage. These proteins are Matrix Gla Protein (MGP), Cartilage Oligomeric Matrix 
Protein (COMP), Cartilage Intermediate Layer Protein 1 (CILP1), Prolargin (PRELP), 280 
Dermcidin (DCD), Fibronectin (FINC), clusterin (CLUS), Glia Derived Nexin (GDN) 
and Collagen Alpha-1 (II) Chain (CO2A1). The list of endogenous peptides included in 
this targeted analysis is detailed in Table 2.  
The area under the curve for the endogenous peptides was plotted for each peptide in 
samples from the UZ and WZ of OA and healthy donors. Certain peptides belonging to 285 
CILP1 (DEGDTFPLR) and PRELP (DSNKIETIPN, DLENVPHLR) were found to be 
mostly increased in the WZ of OA cartilages when compared to UZ and healthy donors. 
To confirm these results and normalise the data, we dev loped a scheduled MRM method 
and incorporated peptides labelled with heavy stable isotopes as internal standards for the 
quantification.  290 
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3.3 Quantification of endogenous peptides in cartilage secretomes 
The validation study was carried out using the scheduled MRM method and stable isotope 
labelled peptide standards on 62 secretome samples obtained from hip (n=33) and knee 
(n=29) cartilage. All the quantification data (expressed as peak area ratios of light/heavy 
peptides) from the different peptides in the secretom  of different zones of OA cartilage 295 
(UZ and WZ) and healthy donors in the different joints are showed in Supplementary 
Table 3. After statistical analysis of the results, four endogenous peptides were found to 
be differentially released from OA cartilage compared to healthy tissue with a significant 
p-value. Among these, two peptides from PRELP (DSNKIETIPN and DLENVPHLR) 
and one from MGP (NTFISPQQR) were differentially released independently of the OA 300 
cartilage zones (Figure 2A). Furthermore, the same tendency was found in the OA WZ 
compared to control donors for these peptides and the peptide DEGDTFPLR from CILP1. 
All of them were found increased in the OA WZ vs healthy cartilage (Figure 2B). Finally, 
the peptide DSNKIETIPN (PRELP) was differentially released in the UZ compared to 
normal cartilage, and also between the two OA cartilage zones.  305 
 
Figure 2. Differential endogenous peptides released from osteoarthritic articular 
cartilage. Scattering plots representing the different abundance of each peptide in the 
cartilage secretomes. A) Comparison between OA (n=44) and normal tissue (n=18). B) 
OA samples were classified into those from the unwounded zone of the tissue (UZ, n=22) 310 
and from the wounded (WZ, n=22). The results are expressed as area ratios (light/heavy, 
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L/H). Data were analyzed using Mann-Whitney test and plotted as means ± SEM for each 
condition. p*<0.05, p**<0.005 p***<0.0005. (Two-column figure). 
 
3.4 Differential release of endogenous peptides from knee and hip articular 315 
cartilages 
The targeted peptide quantification evidenced a differential release of certain neopeptides 
depending on the joint that was studied (p<0.05), which are shown in the Supplementary 
Table 4 and Supplementary Figure 2. In all cases, the release was higher from the knee 
tissue. Comparison of the conditioned media of all knee (n=29) and hip (n=33) cartilage 320 
samples demonstrated the increased release from knee of endogenous peptides 
corresponding to the MGP (NANTFISPQQR and NTFISPQQR), COMP 
(AEPGIQLKAV) and PRELP (DSNKIETIPN), with fold changes ranging from 2.29 to 
5.11 (Supplementary Figure 2A). In OA cartilage, the peptide AEPGIQLKAV (COMP) 
has a remarkable 8-fold change ratio higher in knee vs hip, while DSNKIETIPN from 325 
PRELP and GEDQYYLRVTTV and ASHTSDSDVPSGVTEV from CLUS also showed 
significant differences (Supplementary Figure 2B). Considering only the healthy tissues 
(knee n=5 and hip n=13), one peptide was increased in the knee samples (NTFISPQQR, 
from MGP) with a fold ratio of 3.54 (Supplementary Figure 2C).  
Given these joint-characteristic profiles, the differences in the release of peptides were 330 
examined independently in hip and knee samples. In hip, two peptides from CLUS were 
increased in the conditioned media of healthy cartilage compared to OA tissue: 
ASHTSDSDVPSGVTEVV and GEDQYYLRVTTV (Figure 3A). When the different 
zones in the diseased cartilage were taken together (Figure 3B), these two peptides 
showed a significant lower release from the wounded zone of the tissue (WZ). The same 335 
happens with another peptide from CLUS, ASHTSDSDVPSGVTEV, and the peptide 




Figure 3. Differential endogenous peptides released from hip articular cartilage. 
Scattering plots showing the abundance of each peptide in hip cartilage secretomes. A)340 
Comparison between OA (n=20) and normal tissue (n=13). B) OA samples were 
classified into those from unwounded zones (UZ, n=10) or wounded zones (WZ, n=10). 
The results are expressed as area ratios (light/heavy, L/H). Data were analyzed using 
Mann-Whitney test and plotted as means ± SEM for each condition. P*<0.05 and 
p**<0.005. (two-column figure). 345 
 
In knee samples, two endogenous peptides from PRELP were significantly increased in 
the conditioned media of OA tissue: DSNKIETIPN and DLENVPHLR (Figure 4A). 
Considering the two zones of OA tissue separately, these two peptides showed an 
enhanced release specifically from the WZ (Figure 4B). Interestingly, the peptide 350 
DSNKIETIPN exhibited the most significant differences, which were also detectable in 
samples from the UZ of OA tissue. The peptide DEGDTFPLR from CILP1 displayed a 





Figure 4. Differential endogenous peptides released from knee articular cartilage. 
Scattering plots showing the abundance of each peptide in knee cartilage secretomes. A) 
Comparison between OA (n=24) and normal tissue (n=5). B) OA samples were classified 
into those from unwounded zones (UZ, n=12) or wounded zones (WZ, n=12). The results 
are expressed as area ratios (light/heavy, L/H). Data were analyzed using Mann-Whitney 360 
test and plotted as means ± SEM for each condition. P*<0.05 and p**<0.005. (Two-
column figure). 
 
3.5 Value of the identified peptides as biomarkers of articular cartilage degradation 
To evaluate the putative biomarker value of the endogenous peptides that have been 365 
identified, an analysis by receiver operator characteristic (ROC) curves was performed. 
As illustrated in Figure 5A, the peptide DSNKIETIPN showed an area under the curve 
(AUC) of 0.781 [IC 95%: (0.660-0.901), p=0.001], being the best candidate to 
discriminate healthy vs OA tissue independently of the target joint. Considering only the 
knee, the AUC of this peptide increased up to 0.834 (Figure 5B). On the other hand, two 370 
peptides from CLUS (ASHTSDSDVPSGVTEVV and GEDQYYLRVTTV) displayed 




Figure 5. Receiver operator characteristic (ROC) curves of the biomarker peptides 
identified in this work. A) The release of four peptides discriminates OA vs healt y 375 
articular cartilage with significant p value (p<0.05), B) The peptide DSNKIETIPN from 
prolargin differentiates knee OA from healthy tissue, and C) Two peptides from clusterin 
discriminate hip OA from healthy tissue. (1 5 or two-column figure) 
 
Finally, we also performed this analysis by splitting the OA tissue in zones 380 
(Supplementary Figure 3). In this case, again the best results were obtained for the peptide 
DSNKIETIPN in knee, showing a good biomarker value (AUC=0.783) in OA but 
macroscopically normal cartilage. Comparing healthy knee tissue with the damaged 
zones of knee OA, this AUC increased up to 0.891. In hip, the performance of 





Peptides are constantly generated in vivo either by active synthesis and proteolytic 
processing of larger precursor proteins, often yielding protein fragments that mediate a 
variety of physiological or pathological functions. Given that abnormal proteolysis is a 390 
hallmark of various diseases, many studies have now turned to the focus on the peptidome 
[18] as a source of biomarkers. The investigation of peptides in a system-wide manner 
could facilitate the identification of potential biomarkers, the identification of protease-
substrate relationships and the profiling of pathological degradation processes.  
Considering that the process of articular cartilage ECM degradation is a hallmark for OA, 395 
we aimed to perform the first neo-peptidomic profiling of this pathological situation 
without the use of any in vitro stimulus. Previous studies on endogenous peptides in OA 
have all employed models using either well known OA-related proteinases [19] or 
inducers of cartilage degradation such as mechanical damage or proinflammatory 
cytokines [20, 21]. Our two-step peptidomic analysis started with a first discovery phase 400 
on conditioned media from cartilage explants, identifyi g 1175 different peptides 
corresponding to 101 unique proteins. This is, to our knowledge, the deepest 
characterization of cartilage neopeptides. Interestingly, in general we detected more 
peptides and with higher signals in secretomes from knee samples than from hip 
(Supplementary Figures 1 and 2), which depicts the diff rences between these two joints 405 
and also indicates a higher turnover in the knee that could not been revealed in previous 
proteomic analyses performed directly on the tissue [3, 22]. Data mining showed that 
most of the identified proteins were cartilage ECM proteins or proteins with well-
established matrix functions, such as collagens and proteoglycans. Although some of the 
parental proteins of many of these neopeptides havebeen reported for the first time in 410 
cartilage-derived samples (such as salivary acidic proline-rich phosphoprotein 1/2) most 
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of them had been previously associated with OA: type II collagen, proteoglycan 4, 
fibronectin or cartilage oligomeric matrix protein. Notably, our list of neopeptides 
includes the detection of previously known OA biomarkers, such as CTXII (peptides 
GPDPLQYMRA, DPLQYMRA and SAFAGLGPRE, from the C-telopeptide fragment 415 
of type II collagen). Altogether, this further evidences the usefulness of secretome 
analysis as a source of cartilage-characteristic biomarkers [14, 21, 23]. 
Next, in a second validation step, we selected a panel of these endogenous peptides and 
developed a targeted method for their quantification in secretomes. Then, this method 
was applied for an exhaustive analysis on 62 secretom s from articular cartilage, which 420 
allowed to obtain statistically significant results of the differences. Eight endogenous 
peptides were found to be differentially released from OA compared to healthy tissue. 
The metrics obtained in this study are summarized in Table 3.  
Table 3. Endogenous peptides identified as putative OA biomarkers in human articular 
cartilage. Numbers show the p-value calculated in each case.  425 
Peptide markers of OA 
Peptide Protein N vs OA N vs UZ N vs WZ UZ vs WZ 
DEGDTFPLR  CILP1   0.0233  
DSNKIETIPN  PRELP 0.0008 0.049 0.0001 0.0094 
DLENVPHLR  PRELP 0.0376  0.0047  
NTFISPQQR  MGP 0.0327  0.0202  
Peptide markers of Knee OA 
Peptide Protein N vs OA N vs UZ N vs WZ UZ vs WZ 
DEGDTFPLR  CILP1   0.0235  
DSNKIETIPN  PRELP 0.0226  0.0022 0.0012 
DLENVPHLR  PRELP 0.04  0.0127  
Peptide markers of Hip OA 
Peptide Protein N vs OA N vs UZ N vs WZ UZ vs WZ 
ASHTSDSDVPSGVTEVV  CLUS 0.0383  0.0076  
ASHTSDSDVPSGVTEV CLUS   0.0162  
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GEDQYYLRVTTV  CLUS 0.0237  0.0277  
AEPGIQLKAV COMP   0.0194  
N: healthy tissue; UZ: unwounded zone of OA cartilage; WZ: wounded zone of OA cartilage. 
 
Remarkably, we found decreased amounts of three neopeptides from CLUS and one from 
COMP in hip OA samples (Figure 3). This is in accordance with the disease-related 
significant decrease of these two proteins in articular cartilage that has been described 430 
recently [3]. CLUS, also known as Apolipoprotein J, is a secreted protein that regulates 
apoptosis and inflammation. A few studies have observed elevated CLUS in cartilage and 
synovial fluid in early OA [24, 25]. Furthermore, increased CLUS levels in SF and serum 
showed statistically significant associations with joint space narrowing after adjustment 
for age and sex [26]. However, IL-1α-stimulated cartilage explants have shown to 435 
produce decreased levels of CLU compared to untreated cartilage [3, 27]. An analogous 
discrepancy happens with COMP: although this protein is decreased in knee and hip OA 
articular cartilage (p=0.007) [3], it is well known that its elevated levels in serum are 
associated with OA severity [6, 28]. An explanation f r this might be that these higher 
levels of CLUS and COMP in OA SF and plasma could represent the activation of a 440 
compensatory, but ultimately ineffective, protective pathway.  
In knee, we observed the disease-related increase of one neopeptide from CILP1 and two 
from PRELP. This increase was significant from the WZ zones of the tissue in all cases, 
but in the case of the peptide DSNKIETIPN from PRELP it was also detectable in the 
macroscopically normal zone. Furthermore, the ROC analysis showed the best results for 445 
this peptide (Figure 5), with and AUC of 0.834 for the classification of the tissue as OA 
or healthy, with a high specificity (0.821) for OA. Interestingly, DSNKIETIPN was 
identified in a previous study as the relatively most abundant peptide from an i  vitro 
digestion with ADAMTS4 [19]. The contribution of the aggrecanases ADAMTS4 and 
ADAMTS5 to cartilage destruction in OA has been widely established [29, 30], although 450 
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it has not been resolved completely. PRELP is a small leucine-rich proteoglycan highly 
abundant in cartilage [31, 32] that binds the basement membrane heparan sulfate 
proteoglycan perlecan through its N-terminal region, and collagens (type I and II) through 
its 12 leucine-rich repeat (LRR) domains. An increase in DSNKIETIPN, localized in the 
7th LRR domain of the protein, denotes PRELP breakage with a loss of half its LRR 455 
domains for collagen binding. Thus, the statistically significant increase of this 
neopeptide in OA cartilage that we demonstrate in the present work depicts the role of 
PRELP as mediator of ADAMTS4 catabolic effects in articular cartilage.  
5. Conclusions 
We have performed a peptidomic analysis for the discovery and validation of novel 460 
neopeptides associated with the degradation of articular cartilage ECM in osteoarthritis. 
This work has enabled not only to obtain an exhaustive neopeptidome profile of healthy 
and diseased tissues, but also the identification and validation of a panel of eight 
differential endogenous peptides that are released in the pathogenic process. The peptide 
DSNKIETIPN, from Prolargin, showed the best metrics as a biomarker of OA cartilage, 465 
proving to be the most promising candidate for the development of assays aimed at its 
detection and quantification in biological fluids. 
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Supplementary Data 
Supplementary Figure 1.  Multiple Reaction Monitoring (MRM) - mass spectromety 
quantification of endogenous peptides. A) Representative chromatograms of the 
endogenous peptide PRELP_DSNKIETIPN in a pool of secretome samples (n=3) from 
hip (upper row) and knee (lower row). The endogenous peptides (light) are represented 495 
in red, whereas the heavy peptide standards (SIS) are displayed in blue. The amount of 
SIS spiked into each sample was kept constant. B) Chart plot representing the peak area 
ratio normalized to the heavy peptide standard for each type of sample. WZH, wounded 
zone from hip OA; UZH, unwounded zone from hip OA; NH, healthy hip; WZK, 
wounded zone from knee OA; UZK, unwounded zone from knee OA; NK, healthy knee. 500 
Supplementary Figure 2. Differential release of endogenous peptides from hip and 
knee articular cartilages. Scattering plots showing the distribution of the Area 
light/heavy (L/H) ratios of representative endogenous peptides. The data were analyzed 
using Mann-Whitney test and plotted as means ± SEM for each condition. A) Knee (n=29) 
vs hip (n=33), B) OA knee (n=23, 12 WZ and 13 UZ) vs OA hip (n=20, 10 WZ and 10 505 
UZ), and C) Healthy knee (n=5) vs healthy hip (n=13). p* < 0.05, p**<0.005 
p***<0.0005. 
Supplementary Figure 3. Receiver operator characteristic (ROC) curves of the best 
biomarker peptides differentiating disease and zone in knee (A) or hip (B) articular 
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cartilage. The inset tables show the metrics obtained for eachpeptide in normal (healthy), 510 
unwounded (UW) or wounded (W) zones of OA tissue from each joint.  
Supplementary Table 1. Targeted proteomics design. MRM mass spectrometry 
transitions analyzed in this work, and settings for their analysis.  
Supplementary Table 2. Full results from the discovery phase. A) Endogenous 
peptides identified in the secretomes of human articular cartilage. B) Unique proteins 515 
corresponding to the endogenous peptides identified in this work. 
Supplementary Table 3. Quantification data obtained for the panel of peptides 
analyzed by MRM mass spectrometry. Results are expressed in peak area ratios of 
abundance (light/heavy peptides), with a confidence lev l of p<0.05*. 
Supplementary Table 4. Fold changes of endogenous peptides differentially released 520 
from knee and hip articular cartilage with a significant p-value (<0.05). Data obtained 
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